Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of Vaginal Lactobacilli and Estriol (Gynoflor®) for Atrophic Vaginitis in Breast Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with breast cancer on non-steroidal AI therapy (AI therapy start at least 6 months ago, and are scheduled to receive them during the study)~2. Postmenopausal and age ≥52 with cessation of menses for at least 12 months~3. Age 52 - 75 years~4. Clinical symptoms of vaginal atrophy~5. Vaginal pH \> 5.0~6. Karnofsky score ≥80%~7. Signed Informed Consent Form together with contractual capability~Exclusion Criteria:~1. Local or systemic use of any other sexual hormones (estrogens, progestins, androgens), 6 months before and during study~2. Local or systemic use of phytoestrogens or products known for or taken to improve vaginal mucosal function, risk of vaginal infections, or vulvovaginal symptoms, 4 weeks before and during study~3. Local or systemic use of any other anti-infectives, 2 weeks before and during study~4. Use of any other vaginal medication, vaginal rinses and/or moisturizers, gels containing xylocain or other analgesic products to decrease pain during intercourse, 1 week before and during study~5. Known or suspected hypersensitivity or intolerance to the study medications, inclusive their excipients~6. Suspicion of or clinically manifest sexually transmitted infections (infections with Neisseria gonorrhoea, Chlamydia trachomatis, Treponema pallidum, genital herpes, Trichomonas vaginalis, genital condylomata, HIV)~7. Clinical evidence of vaginal infections requiring extra treatment~8. Any infections of the upper genital tract~9. Hysterectomy~10. Genital haemorrhage of unknown origin~11. Malignant or pre-cancerous conditions of the uterus, vulva and/or vagina (PAP smear less than 3 years ago)~12. Acute thrombophlebitis, thromboembolic disorders or a history of these disorders in association with previous use of oestrogen preparations~13. Abuse of alcohol or drugs~14. All chronic illnesses which could influence the absorption, distribution, biotransformation or elimination of the test preparation~15. Patient has a condition or is in a situation which, in the investigator's opinion, may put the patient in significant risk, may confound the study result, or may interfere significantly with the patient's participation in the study~16. BMI lower than 18.5 or higher than 30~17. Patient on steroidal AIs (aromasin)~18. Vulvo-dermatological conditions (like Lichen sclerosus, Lichen rubrus, Psoriasis)~19. Genital prolapses~20. Endometriosis~21. Use of antibiotics or chemotherapeuticals which are harmful to lactobacilli~22. Participation of patient in another investigational drug study, with the exception of treatment optimisation studies with non-steroidal aromatase inhibitors (AI)s~23. Previous participation in this study~24. Patient is a relative of, or staff directly reporting to the investigator~25. Patient is an employee of the sponsor

- Gender: FEMALE
- Minimum Age: 52 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Gynoflor (Type: EXPERIMENTAL): Gynoflor vaginal tablets 1/day x 4 weeks, then 3/week for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete